Multiple Disease Markers Analyzed Using Multiplex Serology Panels

Two multiplex infectious-disease serology panels are used to analyze multiple disease markers from a single patient-sample.

BioPlex ToRC Immunoglobulin G (IgG) panel and the BioPlex Herpes virus (HSV)-1 and HSV-2 IgG panel were developed for use on the BioPlex 2200 system, a fully automated random-access platform that employs multiplexing technology. The BioPlex 2200 uses sets of magnetic beads coated with ligands as the basis for a range of autoimmune, infectious disease, and other immunoassays.

The ToRC IgG kit simultaneously detects IgG class antibodies to Toxoplasma gondii, rubella, and Cytomegalovirus (CMV), organisms that can cause a variety of serious conditions in an unborn fetus, including blindness, brain damage, and death. The HSV-1 and HSV-2 IgG kit utilizes type-specific proteins to simultaneously detect and differentiate IgG class antibodies to the two most common herpes subtypes, HSV-1 and HSV-2.

"The launch of the ToRC IgG kit and upcoming launch of the HSV-1 and HSV-2 IgG kits are two significant steps in expanding the BioPlex 2200 serology testing menu," said John Goetz, Bio-Rad vice-president and group manager, clinical diagnostics. "Using these two products, laboratories will be able to take advantage of the power and efficiency of multiplexing."

Bio-Rad Laboratories (Hemel Hempstead, UK) announced U.S. Food and Drug Association (FDA; Rockville, MD, USA) clearance of the two multiplex infectious-disease serology panels.

Bio-Rad Laboratories, Inc. manufactures and distributes a broad range of products for clinical diagnostic and life science research. Bio-Rad supplies hospitals, universities, research institutions, as well as biotechnology and pharmaceutical companies.

Related Links:
Bio-Rad Laboratories
U.S. Food and Drug Association